Inclusion Criteria:  Men and women of age ≥ 18 years old. Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology. Cirrhosis of any aetiology may be included. However, patients with cirrhosis due to autoimmune hepatitis must be on stable corticosteroid dose for ≥3-month period before study inclusion. Child-Pugh A, B patients or Child-Pugh C patients (up to 12 points). Patients with a recent history of cirrhosis decompensation or/and recent discharge from the hospital for an episode of acute cirrhosis decompensation Participants able to give informed consent  Exclusion Criteria:  Patients with ACLF according to the criteria published by Moreau et al, Gastro 2013 Bacterial infection within 7 days before study inclusion. Gastrointestinal bleeding within 10 days before study inclusion. Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the New-Haven classification. 5. Patients with active hepatocellular carcinoma or history of hepatocellular carcinoma that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria.  6. Patients with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD >2, chronic kidney disease with serum creatinine >2mg/dL or under renal replacement therapy.  7. Patients with current extra hepatic malignancies including solid tumours and hematologic disorders.  8. Patients with mental incapacity, language barrier, or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study.  9.Refusal or inability to give informed consent